AVE 0.00% 0.3¢ avecho biotechnology limited

Ann: December 2022 Quarterly Activities Report & Appendix 4C, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,963 Posts.
    lightbulb Created with Sketch. 632
    Nothing to positive here in relation to future business revenue of any kind:

    "As noted in 8.6.1, operating expenses are expected to be lower in early 2023 than
    the previous quarter. The Directors continue to review the Company’s costs and expenses
    and assess potential sources of revenues and funding including application for research and
    development incentive application for 2022. The Company’s current cash balances are
    expected to be sufficient to cover the operating expenses in the near future. However, the
    Company has a successful history of capital raising and if required the Company will raise
    additional capital by one of or a combination of the following: placement of shares, rights
    issue, share purchase plan. In addition, the Company also have following funding options
     Potential debt financing of the R&D tax incentive so the Group can receive the money
    in advance; and
     Defer certain R&D expenditure to the future to reduce the cash outflows.
    The Directors will continue to monitor the ongoing funding requirements of the Company".
    Kens
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $1.32K 440K

Buyers (Bids)

No. Vol. Price($)
30 40522233 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 40065430 31
View Market Depth
Last trade - 14.05pm 15/11/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.